Floxuridine coupling with lactosaminated human albumin to increase drug efficacy on liver micrometastases

Digestive and Liver Disease

Volumn 34, Issue 6, 2002, Pages 439-446

  Di Stefano, G ^a   Busi, C ^a   Fiume, L ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Colorectal cancer; Floxuridine; Liver micrometastases; Regional anticancer chemotherapy

Indexed keywords

ASIALOGLYCOPROTEIN RECEPTOR; DRUG CARRIER; FLOXURIDINE; FLUOROPYRIMIDINE DERIVATIVE; GALACTOSE; HUMAN ALBUMIN; LACTOSE; NUCLEOSIDE ANALOG;

AMINATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER ADJUVANT THERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TRANSPORT; FEMALE; HEPATIC VEIN; INFERIOR CAVA VEIN; LIVER BLOOD FLOW; LIVER CELL; LIVER METASTASIS; LIVER SINUSOID; MOUSE; NONHUMAN; RAT; SYSTEMIC CIRCULATION;

EID: 0036083670     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(02)80042-1     Document Type: Article

References (48)

1. Adjuvant chemotherapy for resectable rectal and colonic cancer
2. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer
3. The vascularization of liver metastases. Histological investigation of gelatin-injected liver specimens with special regard to the vascularization of micrometastases
4. A randomised controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer
5. Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma
6. Portal vein chemotherapy for colorectal cancer: A meta-analysis of 4000 patients in 10 studies
7. Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: A randomised trial
8. Enhanced inhibition of virus DNA synthesis in hepatocytes by trifluorothymidine coupled to asialofetuin
9. Hepatocyte targeting of adenine-9-β-D-arabinofuranoside 5′-monophosphate (ara-AMP) coupled to lactosaminated albumin
10. Coupling of the antiviral drug ara-AMP to lactosaminated albumin leads to a specific uptake in rat and human hepatocytes
11. Liver targeting of nucleoside analogues coupled to galactosyl terminating macromolecules: A new approach to the treatment of a chronic viral hepatitis
12. Liver targeting of antiviral nucleoside analogues through the asialoglycoprotein receptor
13. Physical and chemical studies on ceruloplasmin. J. Metabolic studies on the sialic acid-free ceruloplasmin in vivo
14. Asialoglycoprotein receptor
15. Coupling to lactosaminated poly-L-lysine reduces the toxic effects of ribavirin on red blood cells
16. 3H]thymidine incorporation into DNA of rat regenerating liver by 2′,2′-difluorodeoxycytidine coupled to lactosaminated poly-L-lysine
17. Enhanced liver blood concentrations of adenine arabinoside accomplished by lactosaminated poly-L-lysine coupling: Implications for regional chemotherapy of hepatic micrometastases
18. Coupling of 5-fluoro 2′-deoxyuridine to lactosaminated poly-L-lysine: An approach to a regional, non-invasive chemotherapy of liver micrometastases
19. Chemotherapy of neoplastic diseases
20. Inhibition of hepatitis B virus replication by vidarabine monophosphate conjugated with lactosaminated serum albumin
21. Adenine arabinoside monophosphate coupled to lactosaminated albumin, administered for 4 weeks to patients with chronic type B hepatitis, decreased viremia without producing significant side effects
22. Efficacy and safety of L-HSA-ara-AMP in chronic hepatitis B patients non responder to interferon therapy: A randomised clinical trial
23. Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines
24. Proteins containing reductively aminated disaccharides. Synthesis and chemical characterisation
25. Effect of reductive lactosamination on the hepatic uptake of bovine ribonuclease A dimer
26. Coupling of antiviral nucleoside analogs to lactosaminated human albumin by using the imidazolides of their phosphoric esters
27. Drug targeting in antiviral chemotherapy. A chemically stable conjugate of 9-β-D-arabinofuranosyl-adenine accomplishes a selective delivery of the drug to liver cells
28. The reliability of molecular weight determinations by dodecyl sulphate-polyacrylamide gel electrophoresis
29. Protein labelling by reductive alkylation
30. Tumour induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure
31. Inhibition of establishment and growth of mouse liver metastases after treatment with interferon gamma and β-1,3-D-glucan
32. Incorporation of pyrimidine deoxyribonucleosides into liver lipids and other components
33. A study of the conditions and mechanisms of diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid
34. Lactosaminated human serum albumin as hepatotropic drug carrier. Rate of uptake by mouse liver
35. Distribution of a conjugate of 9-β-D-arabinofuranosyladenine 5′-monophosphate (ara-AMP) with lactosaminated albumin in parenchymal and sinusoidal cells of rat liver
36. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro 2′-deoxyuridine and 5-fluorouracil
37. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients
38. Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer
39. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases
40. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial
41. A controlled comparison of 5-fluoro-2′-deoxyuridine therapy administered by rapid intravenous injection and by continuous intravenous infusion
42. Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2′-deoxyuridine ± N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26
43. Biliary sclerosis in patients receiving hepatic arterial infusion of floxuridine
44. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer
45. Hepatobiliary toxicity of 5-fluoro-2′-deoxyuridine. Intra-arterial versus portal venous routes of infusion
46. The terminal distribution of hepatic artery with special reference to arterio-portal anastomosis
47. The microcirculatory hepatic unit
48. The peribiliary vascular plexus: The microvascular architecture of the bile duct in the rabbit and in clinical cases